AR042037A1 - Profarmaco de celecoxib - Google Patents

Profarmaco de celecoxib

Info

Publication number
AR042037A1
AR042037A1 ARP030104171A ARP030104171A AR042037A1 AR 042037 A1 AR042037 A1 AR 042037A1 AR P030104171 A ARP030104171 A AR P030104171A AR P030104171 A ARP030104171 A AR P030104171A AR 042037 A1 AR042037 A1 AR 042037A1
Authority
AR
Argentina
Prior art keywords
celecoxib
profarmaco
pharmaceutically acceptable
cox
prodrugs
Prior art date
Application number
ARP030104171A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR042037A1 publication Critical patent/AR042037A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members

Abstract

Profármacos del fármaco inhibidor selectivo de la COX-2 celecoxib y sus sales farmacéuticamente aceptables. Reivindicación 1:Un compuesto que tiene la fórmula 1 o una sal farmacéuticamente aceptable del mismo.
ARP030104171A 2002-11-12 2003-11-12 Profarmaco de celecoxib AR042037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42570302P 2002-11-12 2002-11-12

Publications (1)

Publication Number Publication Date
AR042037A1 true AR042037A1 (es) 2005-06-08

Family

ID=32313040

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104171A AR042037A1 (es) 2002-11-12 2003-11-12 Profarmaco de celecoxib

Country Status (17)

Country Link
US (1) US20040092566A1 (es)
EP (1) EP1562910A1 (es)
JP (1) JP2006508123A (es)
KR (1) KR20050072823A (es)
CN (1) CN1711247A (es)
AR (1) AR042037A1 (es)
AU (1) AU2003291278A1 (es)
BR (1) BR0316155A (es)
CA (1) CA2505635A1 (es)
CO (1) CO5700738A2 (es)
MX (1) MXPA05004991A (es)
NO (1) NO20052813L (es)
PL (1) PL376918A1 (es)
RU (1) RU2005114398A (es)
TW (1) TW200424179A (es)
WO (1) WO2004043934A1 (es)
ZA (1) ZA200503188B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303591A1 (en) * 2002-12-30 2004-07-29 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
WO2006055381A2 (en) * 2004-11-16 2006-05-26 Merck & Co., Inc. Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
CN101805290A (zh) * 2010-04-01 2010-08-18 中国人民解放军第四军医大学 氨基磺酰吡唑类化合物及其用途
BRPI1003050B1 (pt) * 2010-08-04 2021-05-25 Universidade Federal De Minas Gerais Compostos derivados do ácido araquidônico substituídos com análogos de coxibes para tratamento de dor
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CN104892514A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种咪唑类新化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719496T2 (de) * 1996-04-12 2004-04-08 G.D. Searle & Co., Chicago N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULPHONYLPROPYLAMID und sein NATRIUMSALZ ALS PRO-PHARMAKON VON COX-2 INHIBITOREN

Also Published As

Publication number Publication date
RU2005114398A (ru) 2006-01-20
AU2003291278A1 (en) 2004-06-03
TW200424179A (en) 2004-11-16
PL376918A1 (pl) 2006-01-09
WO2004043934A1 (en) 2004-05-27
MXPA05004991A (es) 2005-08-02
NO20052813L (no) 2005-08-02
CA2505635A1 (en) 2004-05-27
KR20050072823A (ko) 2005-07-12
BR0316155A (pt) 2005-09-27
NO20052813D0 (no) 2005-06-10
ZA200503188B (en) 2006-11-29
JP2006508123A (ja) 2006-03-09
CN1711247A (zh) 2005-12-21
CO5700738A2 (es) 2006-11-30
US20040092566A1 (en) 2004-05-13
EP1562910A1 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
ES2545205T3 (es) Combinación de azelastina y ciclesonida
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
AR046970A1 (es) Esteres de fosfato de florfenicol
HN2003000408A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
RS52274B (en) UNIT DIARYLHIDANTOIN
PT1193270E (pt) Pirrolobenzodiazepinas
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
CR6682A (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorios, autoinmunes y respiratorias
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
RS52931B (en) VIRAL POLYMERASE INHIBITORS
NI200500031A (es) Nuevos procesos para la sintesis de ivabradine y ademas sales que la contienen con un acido aceptable farmaceuticamente.
ES2571220T3 (es) Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina
AR121226A1 (es) Compuestos y usos de estos
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
DE60027144D1 (de) Hydroxamsäure-derivate
UY29774A1 (es) Inhibidor de atm
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
AR053989A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure